Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation är ett kutan tillstånd som kännetecknas av ökat pigment i huden efter en inflammation. Postinflammatory hyperpigmentation kan uppstå efter långvarig solexponering, inflammation eller andra hudskador, inklusive sådana som är relaterade till akne. Människor med mörkare hudtoner är vanligtvis mer benägna att utveckla hyperpigmentering vid överdriven solexponering.
☆ AI Dermatology — Free Service
I Stiftung Warentest-resultaten 2022 från Tyskland var konsumentnöjdheten med ModelDerm bara något lägre än med betalda telemedicinkonsultationer.
I Stiftung Warentest-resultaten 2022 från Tyskland var konsumentnöjdheten med ModelDerm bara något lägre än med betalda telemedicinkonsultationer.
relevance score : -100.0%
ReferencesPostinflammatory hyperpigmentation (PIH) är ett vanligt hudproblem som uppstår efter hudinflammation eller skada. Det kan vara bestående och är vanligare hos personer med mörkare hudtoner (Fitzpatrick skin types III–VI). Även om det ofta förbättras av sig själv kan det ta tid, så behövs ofta behandling under en längre period. Att kombinera olika behandlingar fungerar bäst.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatorisk hyperpigmentering är en vanlig följd av hudinflammation. Den drabbar personer med mörk hudton oftare och kan vara mer uttalad. Studier visar att postinflammatorisk hyperpigmentering är en av de främsta anledningarna till att personer med mörkare hudtoner söker hudvård. Tidig behandling är avgörande och inleds vanligtvis med att kontrollera det underliggande inflammatoriska tillståndet. Första steget är ofta topikala medel som ljusar huden i kombination med solskydd. Sådana medel, såsom hydroquinone, azelaic acid, kojic acid, arbutin och licorice extracts, kan effektivt minska överdriven pigmentering. Dessutom används retinoider, mequinol, ascorbic acid, niacinamide, N‑acetyl glucosamine och soy som depigmenteringsmedel, och nya behandlingar utvecklas kontinuerligt. Även om topikala behandlingar vanligtvis är effektiva för hyperpigmentering på ytnivå, kan procedurer (laser, chemical peel) vara nödvändiga vid envisa fall. Det är viktigt att vara försiktig med dessa behandlingar för att undvika irritation och förvärring av postinflammatorisk hyperpigmentering.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
